Dosing & Uses
Dosage Forms & Strengths
oral spray
- 0.125 mg/mL (0.125 mg/spray)
Excessive Gastric Secretion
1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Other Indications & Uses
Peptic ulcer disease, abdominal cramps, spastic bladder, cystitis, pylorospasm, IBS, biliary and renal colic, urinary incontinence, Parkinsonism, acute rhinitis, sialorrhea, hyperhidrosis, cholinergic poisoning
Heat prostration may be caused due to suppression of sweating
Dosage Forms & Strengths
oral spray
- 0.125 mg/mL (0.125 mg/spray)
Excessive Gastric Secretion
<12 years: Safety and efficacy not established
12 years or older: 1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Avoid; high incidence of anticholinergic effects; avoid except in short-term situations to decrease secretions (Beers Criteria)
Excessive gastric secretion: 1-2 oral sprays (0.125-0.25 mg) q4hr PRN, not to exceed 12 sprays/day
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (7)
- glucagon
glucagon increases toxicity of hyoscyamine spray by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .
- glucagon intranasal
glucagon intranasal increases toxicity of hyoscyamine spray by Other (see comment). Avoid or Use Alternate Drug. Comment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. .
- glycopyrronium tosylate topical
glycopyrronium tosylate topical, hyoscyamine spray. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- pramlintide
pramlintide, hyoscyamine spray. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.
- revefenacin
revefenacin and hyoscyamine spray both decrease cholinergic effects/transmission. Avoid or Use Alternate Drug. Coadministration may cause additive anticholinergic effects.
- secretin
hyoscyamine spray decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.
- umeclidinium bromide/vilanterol inhaled
hyoscyamine spray, umeclidinium bromide/vilanterol inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Concomitant use with other anticholinergic-containing drugs may lead to additive anticholinergic adverse effects.
Monitor Closely (98)
- abobotulinumtoxinA
abobotulinumtoxinA increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .
- aclidinium
hyoscyamine spray and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- amantadine
hyoscyamine spray, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced CNS side effects.
- amitriptyline
hyoscyamine spray and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- amoxapine
hyoscyamine spray and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- anticholinergic/sedative combos
anticholinergic/sedative combos and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- aripiprazole
aripiprazole increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor. - atracurium
atracurium and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine
atropine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna alkaloids
belladonna alkaloids and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna and opium
hyoscyamine spray and belladonna and opium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- benperidol
benperidol increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor. - benztropine
benztropine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- bethanechol
bethanechol increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- buprenorphine, long-acting injection
buprenorphine, long-acting injection increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of buprenorphine with anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
- carbachol
carbachol increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- cevimeline
cevimeline increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- chlorpromazine
chlorpromazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor. - cisatracurium
cisatracurium and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- clomipramine
hyoscyamine spray and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- clozapine
clozapine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor. - cyclizine
cyclizine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- cyclobenzaprine
cyclobenzaprine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- darifenacin
darifenacin and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- desipramine
hyoscyamine spray and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- dicyclomine
dicyclomine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- donepezil
donepezil increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- donepezil transdermal
donepezil transdermal, hyoscyamine spray. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dosulepin
hyoscyamine spray and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- doxepin
hyoscyamine spray and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- droperidol
droperidol increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor. - echothiophate iodide
echothiophate iodide increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- fesoterodine
fesoterodine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- flavoxate
flavoxate and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- fluphenazine
fluphenazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor. - galantamine
galantamine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- glycopyrrolate
glycopyrrolate and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- glycopyrrolate inhaled
glycopyrrolate inhaled and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- haloperidol
haloperidol increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. - henbane
henbane and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- homatropine
homatropine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- huperzine A
huperzine A increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- hydroxyzine
hydroxyzine and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- iloperidone
iloperidone increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor. - imipramine
hyoscyamine spray and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ipratropium
hyoscyamine spray and ipratropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- levodopa
hyoscyamine spray, levodopa. Other (see comment). Use Caution/Monitor. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .
- lofepramine
hyoscyamine spray and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- loxapine
loxapine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor. - loxapine inhaled
loxapine inhaled increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. - maprotiline
hyoscyamine spray and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- meclizine
hyoscyamine spray and meclizine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- methscopolamine
hyoscyamine spray and methscopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- metoclopramide intranasal
hyoscyamine spray will decrease the level or effect of metoclopramide intranasal by Other (see comment). Use Caution/Monitor. Coadministration of metoclopramide intranasal with drugs that impair GI motility may decrease systemic absorption of metoclopramide. Monitor for reduced therapeutic effect.
- neostigmine
neostigmine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- nortriptyline
hyoscyamine spray and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- olanzapine
olanzapine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor. - oliceridine
hyoscyamine spray increases toxicity of oliceridine by Other (see comment). Use Caution/Monitor. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics.
- onabotulinumtoxinA
onabotulinumtoxinA and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor.
- orphenadrine
hyoscyamine spray and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin
hyoscyamine spray and oxybutynin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin topical
hyoscyamine spray and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin transdermal
hyoscyamine spray and oxybutynin transdermal both decrease cholinergic effects/transmission. Use Caution/Monitor.
- paliperidone
paliperidone increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor. - pancuronium
hyoscyamine spray and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- perphenazine
perphenazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor. - physostigmine
physostigmine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pilocarpine
pilocarpine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pimozide
pimozide increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor. - prabotulinumtoxinA
hyoscyamine spray, prabotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.
- pralidoxime
hyoscyamine spray and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.
- prochlorperazine
prochlorperazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. - promethazine
promethazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
- propantheline
hyoscyamine spray and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- protriptyline
hyoscyamine spray and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
- pyridostigmine
pyridostigmine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- quetiapine
quetiapine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor. - rapacuronium
hyoscyamine spray and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- rimantadine
hyoscyamine spray, rimantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced CNS side effects.
- risperidone
risperidone increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor. - rivastigmine
rivastigmine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- rocuronium
hyoscyamine spray and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- scopolamine
hyoscyamine spray and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- solifenacin
hyoscyamine spray and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.
- succinylcholine
succinylcholine increases and hyoscyamine spray decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- thioridazine
thioridazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor. - thiothixene
thiothixene increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor. - tiotropium
hyoscyamine spray and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tolterodine
hyoscyamine spray and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trazodone
hyoscyamine spray and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trifluoperazine
trifluoperazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor. - trihexyphenidyl
hyoscyamine spray and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trimipramine
hyoscyamine spray and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- trospium chloride
hyoscyamine spray and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.
- umeclidinium bromide
umeclidinium bromide and hyoscyamine spray both decrease cholinergic effects/transmission. Use Caution/Monitor. If possible, avoid coadministration of additional anticholinergic agents
- vecuronium
hyoscyamine spray and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ziprasidone
ziprasidone increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.
hyoscyamine spray decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
hyoscyamine spray decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.
Minor (4)
- dimenhydrinate
dimenhydrinate increases toxicity of hyoscyamine spray by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- donepezil
donepezil decreases effects of hyoscyamine spray by pharmacodynamic antagonism. Minor/Significance Unknown.
- galantamine
galantamine decreases effects of hyoscyamine spray by pharmacodynamic antagonism. Minor/Significance Unknown.
- rimantadine
rimantadine increases effects of hyoscyamine spray by pharmacodynamic synergism. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Headache
Nervousness
Blurred vision
Cycloplegia/mydriasis
Increased IOP
Tachycardia
Urinary retention
Xerostomia
Warnings
Contraindications
Glaucoma, obstructive uropathy, GI obstruction, myasthenia gravis, toxic megacolon, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis
Cautions
Autonomic neuropathy, hiatal hernia, reflux esophagitis, renal dz, hyperthyroidism, tachyarrhythmia, CHF, salivary secretion disorder, BPH
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excreted in breast milk, use caution (may suppress lactation)
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Parasympatholytic, atropine-like effects, especially peripherally, blocks the action of ACh at parasympathetic sites in smooth muscle, secretory glands, and CNS
Pharmacokinetics
Absorption: rapid & complete
Half-Life: 2-3.5 hr
Protein Bound: 50%
Metabolism: Partially hydrolyzed to tropic acid & tropine
Excretion: Urine
Vd
- Adults: 1.2-1.9 L/kg
- Children 3.5-16 yo: 1.1-3.7 L/kg
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Symax Duotab oral - | 0.125 mg-0.25 mg (0.375 mg) tablet |  | |
| Ed-Spaz oral - | 0.125 mg tablet |  | |
| Symax-SR oral - | 0.375 mg tablet |  | |
| Symax-SL sublingual - | 0.125 mg tablet |  | |
| Symax Fastabs oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate sublingual - | 0.125 mg tablet |  | |
| hyoscyamine sulfate sublingual - | 0.125 mg tablet |  | |
| hyoscyamine sulfate sublingual - | 0.125 mg tablet |  | |
| hyoscyamine sulfate sublingual - | 0.125 mg tablet |  | |
| Hyosyne oral - | 0.125 mg/5 mL elixir |  | |
| Hyosyne oral - | 0.125 mg/mL drops |  | |
| Levbid oral - | 0.375 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg/5 mL elixir |  | |
| hyoscyamine sulfate oral - | 0.125 mg/mL drops |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.125 mg tablet | | |
| hyoscyamine sulfate oral - | 0.125 mg tablet |  | |
| hyoscyamine sulfate oral - | 0.375 mg tablet | | |
| hyoscyamine sulfate oral - | 0.375 mg tablet |  | |
| Levsin oral - | 0.125 mg tablet | | |
| Oscimin oral - | 0.125 mg tablet |  | |
| Levsin/SL sublingual - | 0.125 mg tablet | | |
| NuLev oral - | 0.125 mg tablet |  | |
| Anaspaz oral - | 0.125 mg tablet |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
hyoscyamine injection
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
